41 patents
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
18 Jan 24
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond Schuch
Filed: 18 Aug 23
Utility
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
28 Nov 23
The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration.
Michael Wittekind, Adam Vigil
Filed: 14 Mar 14
Utility
Gram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serum
3 Oct 23
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond Schuch
Filed: 29 Mar 19
Utility
Biofilm Prevention, Disruption and Treatment with Bacteriophage Lysin
7 Sep 23
The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2.
Raymond SCHUCH, Robert C. NOWINSKI, Michael WITTEKIND, Babar KHAN, Jimmy ROTOLO
Filed: 11 Nov 22
Utility
MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
7 Sep 23
Disclosed herein are preventing or treating a bacterial infection caused by at least one species of Gram-positive bacteria, the method comprising co-administering to a subject diagnosed with, at risk for, or exhibiting symptoms of a bacterial infection a first amount of a modified lysin polypeptide and a second amount of an antibiotic suitable for the treatment of a Gram-positive bacterial infection.
Raymond SCHUCH
Filed: 18 May 21
Utility
Lysin Polypeptides Active Against Gram-negative Bacteria
16 Feb 23
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa.
Raymond SCHUCH, Simon HOFFENBERG, Michael WITTEKIND
Filed: 8 Jul 22
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
29 Dec 22
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond SCHUCH
Filed: 13 Nov 20
Utility
Antimicrobial, Bacteriophage-derived Polypeptides and Their Use Against Gram-negative and Acid-fast Bacteria
22 Dec 22
Disclosed herein are pharmaceutical compositions comprising an effective amount of an isolated Chp peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs. 81-91 and 94-102, or a modified Chp peptide having about 80% sequence identity therewith, wherein the modified Chp peptide inhibits growth, reduces the population, or kills at least one species of Gram-negative or acid-fast bacteria; and a pharmaceutically acceptable carrier.
Raymond SCHUCH
Filed: 2 Jul 20
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
22 Dec 22
The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL).
Raymond SCHUCH
Filed: 29 Jul 22
Utility
Biofilm prevention, disruption and treatment with bacteriophage lysin
13 Dec 22
The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2.
Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Babar Khan, Jimmy Rotolo
Filed: 22 Apr 19
Utility
Use of Lysin to Restore/augment Antibacterial Activity In the Presence of Pulmonary Surfactant of Antibiotics Inhibited Thereby
17 Nov 22
The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present.
Michael WITTEKIND, Raymond SCHUCH
Filed: 20 May 22
Utility
Therapeutic Protein Formulations Comprising Antibodies and Uses Thereof
1 Sep 22
The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-influenza antibodies or antigen-binding fragments thereof in an amount ranging from 30 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization.
Abraham THARIATH
Filed: 10 Jul 20
Utility
Lysin polypeptides active against Gram-negative bacteria
16 Aug 22
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa.
Raymond Schuch, Simon Hoffenberg, Michael Wittekind
Filed: 9 Jul 20
Utility
Method of Treating and Preventing Bone and Joint Infections
23 Jun 22
The present disclosure is directed to a method of treating or preventing a bone or joint infection, which method comprises: administering a therapeutically effective amount of a PlySs2 lysin comprising the amino acid sequence of SEQ ID NO: 1 or a variant thereof having at least 80% identity to SEQ ID NO: 1, wherein the variant comprises bacteriocidal and/or bacteriostatic activity against the Gram-positive bacteria, to a subject in need thereof, optionally co-administered with one or more antibiotics, wherein the bone or joint infection comprises a Gram-positive bacteria, such as Staphylococcus epidermidis or Staphylococcus aureus.
Raymond SCHUCH
Filed: 10 Apr 20
Utility
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
14 Jun 22
The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present.
Michael Wittekind, Raymond Schuch
Filed: 16 Sep 16
Utility
Method of Treating Infective Endocarditis
26 May 22
The present disclosure is directed to a method of treating or preventing infective endocarditis due to Gram-positive bacteria, such as S. aureus, which method includes administering a therapeutically effective amount of a combination of one or more antibiotics, optionally at a sub-Minimum Inhibitory Concentration (MIC) level, and a PlySs2 lysin, such as a single dose of PlySs2 lysin at a sub-MIC level, wherein the one or more antibiotics and the PlySs2 lysin are administered simultaneously or sequentially to a subject in need thereof in any order.
Raymond SCHUCH
Filed: 20 Mar 20
Utility
Lysins and Derivatives Thereof with Bactericidal Activity Against Pseudomonas Aeruginosa, In the Presence of Human Serum
26 May 22
Disclosed are novel lysin polypeptides active against Gram-negative bacteria, particularly P. aeruginosa, pharmaceutical compositions containing them and methods for their use to treat Gram-negative bacterial infections and more generally to inhibit the growth, or reduce the population, or kill Gram-negative bacteria, including without limitation disrupting biofilms formed by such bacteria.
Raymond SCHUCH
Filed: 3 Apr 20
Utility
Antibodies Useful In Passive Influenza Immunization, and Compositions, Combinations and Methods for Use Thereof
14 Apr 22
Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus.
Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
Filed: 23 Dec 21
Utility
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
15 Feb 22
Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus.
Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
Filed: 5 Nov 19
Utility
Blood Component Potentiation of Lytic Protein Anti-bacterial Activity and Methods and Uses Thereof
27 Jan 22
The present invention provides methods, assays, compositions, formulations, and constructs, particularly lytic peptide constructs, which relate to and are based on the activity and use of blood components, particularly serum albumin and lysozyme, and their activity and use to enhance or synergize with the bacterial killing effect of anti-bacterial lytic proteins and peptides.
Raymond SCHUCH
Filed: 10 Jul 18